drugset / Trial / NCT03573960
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of lenvatinib in participants with recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC).
Timeline
- Start
- 2018-04-01
- Primary completion
- 2025-09-04
- Completion
- 2025-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 24 mg | Oral |